IN2014CN00570A - - Google Patents

Info

Publication number
IN2014CN00570A
IN2014CN00570A IN570CHN2014A IN2014CN00570A IN 2014CN00570 A IN2014CN00570 A IN 2014CN00570A IN 570CHN2014 A IN570CHN2014 A IN 570CHN2014A IN 2014CN00570 A IN2014CN00570 A IN 2014CN00570A
Authority
IN
India
Prior art keywords
therapy regimen
panitumumab
cetuximab
therapy
mutation
Prior art date
Application number
Other languages
English (en)
Inventor
Viladot Clara Montagut
Mestres Joan Albanell
Guerin Ana Rovira
Paricio Beatriz Bellosillo
Massegú Alba Dalmases
Original Assignee
Fundació Inst Mar Dinvestigacions Mèdiques Imim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundació Inst Mar Dinvestigacions Mèdiques Imim filed Critical Fundació Inst Mar Dinvestigacions Mèdiques Imim
Publication of IN2014CN00570A publication Critical patent/IN2014CN00570A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN570CHN2014 2011-08-03 2012-08-02 IN2014CN00570A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11382270A EP2554551A1 (de) 2011-08-03 2011-08-03 Mutationen in dem epidermalen Wachstumsfaktor-Rezeptorgen
PCT/EP2012/065090 WO2013017645A1 (en) 2011-08-03 2012-08-02 Mutations in the epidermal growth factor receptor gene

Publications (1)

Publication Number Publication Date
IN2014CN00570A true IN2014CN00570A (de) 2015-04-03

Family

ID=46640020

Family Applications (1)

Application Number Title Priority Date Filing Date
IN570CHN2014 IN2014CN00570A (de) 2011-08-03 2012-08-02

Country Status (12)

Country Link
US (1) US9765399B2 (de)
EP (3) EP2554551A1 (de)
JP (1) JP6149034B2 (de)
KR (1) KR20140072035A (de)
CN (1) CN103717616B (de)
AU (1) AU2012292024A1 (de)
BR (1) BR112014002373A2 (de)
CA (1) CA2842270C (de)
ES (1) ES2556468T3 (de)
IN (1) IN2014CN00570A (de)
RU (1) RU2014107908A (de)
WO (1) WO2013017645A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
ES2844229T3 (es) 2014-05-13 2021-07-21 Univ Texas Mutaciones génicas y alteraciones en el número de copias de EGFR, KRAS y MET
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
ES2693080T3 (es) * 2014-07-28 2018-12-07 Fundació Institut Mar D'investigacions Mèdiques (Imim) Mutaciones en el dominio extracelular III del gen del receptor del factor de crecimiento epidérmico
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
EP3286219A1 (de) * 2015-04-24 2018-02-28 Merrimack Pharmaceuticals, Inc. Verfahren zur behandlung von patienten mit mutationen in der extrazellulären domäne des epidermalen wachstumsfaktor-rezeptors (egfr) mit einer kombination aus drei vollständig humanen monoklonalen anti-egfr-antikörpern
RU2626682C1 (ru) * 2016-07-20 2017-07-31 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования резистентности опухоли к таргетной терапии цетуксимабом у больных плоскоклеточным раком языка и слизистой дна полости рта
CN111499749B (zh) * 2020-03-13 2021-11-09 浙江大学 一种西妥昔单抗突变体及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101056990A (zh) 2004-03-01 2007-10-17 芝加哥大学 表皮生长因子受体基因启动子的多态性
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
CN101208354A (zh) * 2005-02-24 2008-06-25 安姆根有限公司 表皮生长因子受体突变
CN1737162A (zh) * 2005-03-16 2006-02-22 南京中医药大学附属医院(江苏省中医院) 表皮生长因子受体(egfr)基因测序检测方法
US7981606B2 (en) * 2005-12-21 2011-07-19 Roche Molecular Systems, Inc. Control for nucleic acid testing
JP5596975B2 (ja) * 2006-10-26 2014-10-01 ジェネンテック, インコーポレイテッド 腫瘍と関連している遺伝的変異
WO2008088860A2 (en) 2007-01-18 2008-07-24 University Of Southern California Polymorphisms in the egfr pathway as markers for cancer treatment
EP2126127B1 (de) * 2007-01-25 2016-09-28 Dana-Farber Cancer Institute, Inc. Verwendung von anti-egfr-antikörpern bei der behandlung von durch egfr-mutanten vermittelten krankheiten
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
US8583380B2 (en) * 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options

Also Published As

Publication number Publication date
ES2556468T3 (es) 2016-01-18
KR20140072035A (ko) 2014-06-12
EP2554551A1 (de) 2013-02-06
RU2014107908A (ru) 2015-09-10
EP2739648B1 (de) 2015-09-16
EP2739648A1 (de) 2014-06-11
EP2995623A1 (de) 2016-03-16
AU2012292024A1 (en) 2014-02-27
US20140170662A1 (en) 2014-06-19
WO2013017645A1 (en) 2013-02-07
JP6149034B2 (ja) 2017-06-14
BR112014002373A2 (pt) 2017-02-21
CA2842270C (en) 2019-10-29
CA2842270A1 (en) 2013-02-07
US9765399B2 (en) 2017-09-19
CN103717616B (zh) 2016-06-29
JP2014521342A (ja) 2014-08-28
CN103717616A (zh) 2014-04-09

Similar Documents

Publication Publication Date Title
BR112014002373A2 (pt) mutações no gene do receptor do fator de crescimento epidermal
IL265478A (en) Measurement of protein expression using reagents with barcoded oligonucleotide sequences
WO2013022786A3 (en) Microrna biomarkers
GB201200658D0 (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
MX355416B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
MX349907B (es) Metodo para detectar cancer pancreatico.
ZA201301307B (en) Method for testing reheating crack sensitivity of dissimilar steel
EP3044323A4 (de) Zusammensetzungen und verfahren zur erkennung und quantifizierung von wirtszellenprotein in zelllinien und rekombinante polypeptidprodukte
GB201313477D0 (en) Nanopore biosensors for detection of proteins and nucleic acids
WO2011106738A3 (en) Use of tcr clonotypes as biomarkers for disease
MX2014016036A (es) Sistemas, metodos y equipo para determinar la presencia de fluidos de interes.
WO2013160315A3 (en) Genetic predictors of response to treatment with crhr1 antagonists
EP4563709A3 (de) Methoden und materialien zur beurteilung des allelischen ungleichgewichts
WO2013181576A3 (en) Methods of evaluating and making biologics
AU2012236134A8 (en) Biomarkers for predicting sensitivity to cancer treatments
PH12015501778A1 (en) Markers associated with wnt inhibitors
MX2016011465A (es) Drimenol-sintasas y metodos para producir drimenol.
MX2013008252A (es) Firma de pronostico para la recurrencia de cancer colorrectal.
WO2012162613A3 (en) Detection of sequence variants in the human epidermal growth factor receptor (egfr) gene
WO2012137180A3 (en) Biomarkers of immunotherapy efficacy
WO2015077342A3 (en) Detection of arginine methylation of egfr for prediction of resistance to therapy
MX2015013993A (es) Procedimientos y series para su uso en los mismos.
WO2010144808A3 (en) Identification of dsg-3 as a biomarker for the detection of metastasis in lymph nodes
GB201206323D0 (en) Methods and arrays for use in the same
EP2798078A4 (de) Verfahren und primersatz zur erkennung einer mutation